Impact Factor
2.59
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
0.37
3,308 total citations
h5-index
80
h5 depth signal
Cited share
7.9%
735 of 9,274
Total citations
3,308
Citation footprint
Metric signal
0.39
External metric anchor
Self-citation
4.6%
152 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
10,360
Germany
1,317
China
1,227
Canada
1,226
United Kingdom
1,210
Citing Fields of Research
Kidney Diseases
17,198
Urology
3,816
Transplantation
2,491
Auto-Inflammatory Disorders
2,196
Hematology
2,141
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
34,248
Articles tracked across the journal lifetime
Indexed publication set
9,274
735 cited publications
Last 12 months
4,725
393.8 publications/month
Open access share
0.9%
44 OA publications in the last year
Leading citing country
United States
10,360 citing publications
Leading citing field
Kidney Diseases
17,198 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v1n1, July 1990-
v1n1, July 1990-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Kidney Diseases
Issuing & Sponsoring Bodies
Contributor
American Society of Nephrology
Broad Categories
Nephrology
Urology
Hematology
Transplantation
Auto-Inflammatory Disorders
Cardiology
MeSH Descriptors
Kidney Diseases
Nephrology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1681/asn.0000001306
Open DOI
Glucagon-Like Peptide-1 Receptor Agonists and Multi-hormone Receptor Modulators for Kidney Protection in Nondiabetic Kidney Disease
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), together with newer multi-hormone receptor modulators that target glucose-dependent insulinotropic polypeptide (GIP), glucagon and amylin, have emerged as promising therapies for chr...
03
04
DOI 10.1681/asn.0000001279
Open DOI
Eligibility for Predialysis Care and Effect on Patient Outcomes in Ontario Needs Further Study
05
DOI 10.1681/asn.0000001260
Open DOI
Carry Life UF System
Was not provided for this article.
06
DOI 10.1681/asn.0000001261
Open DOI
Authors' Reply: Carry Life UF System: Potential and Risks of Steady Concentration Peritoneal Dialysis
Was not provided for this article.
07
DOI 10.1681/asn.0000001303
Open DOI
Kidney Protection from Glucagon-Like Peptide-1 Receptor Agonists
08
DOI 10.1681/asn.0000001302
Open DOI
Correction to: IHG-1 Promotes Mitochondrial Biogenesis by Stabilizing PGC-1α
Was not provided for this article.
09
DOI 10.1681/asn.0000001264
Open DOI
β-Blockers in Hemodialysis Outcome Trial
10
DOI 10.1681/asn.0000001265
Open DOI
Authors' Reply: β-Blockers in Hemodialysis Outcome Trial
Bibliographical & Catalog Notes
Title from cover.
Imprint varies.
Latest issue consulted: surrogate of Vol. 16, no. 1 (Jan. 2005).
Supplements accompany some vols.
Also issued online.
Official journal of: the American Society of Nephrology.
Vol. 1, no. 1 (JUL 1990)19910912 Notice not published Printed on acid-free paper